|
|
 |
|
|
|
|
|
|
What we are looking for
Immunology and Inflammation: Pursuit of therapies.
Products in development.
Our R&D efforts in this important area are driven by the pursuit of novel investigational therapies for the treatment of inflammatory and autoimmune disorders. Investigational compounds in development include abatacept, in Phase III clinical trials for the potential treatment of rheumatoid arthritis, and LEA29Y, a therapeutic agent in Phase II clinical development for the potential treatment to prevent solid organ transplant rejection.
A list of interests.
As part of our efforts, we are interested in evaluating innovative therapies for transplant rejection, rheumatoid arthritis and related autoimmune disorders.
|
|
|
|
[Top Page] [Search]
[Index] [Contact] [Home]
Italicized product names are trademarks of Bristol-Myers Squibb Company or one of its divisions or subsidiaries. Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd. Erbitux is a trademark of ImClone Systems Incorporated. EMSAM is a trademark of Somerset Pharmaceuticals, Inc. Glucophage, Glucovance and Metaglip are trademarks of Merck Santé S.A.S., an associate of Merck KGaA of Darmstadt, Germany. Avapro, Avalide and Plavix are trademarks of sanofi-aventis. Sinemet CR is a trademark of Merck & Co., Inc.
© 1999-2008 Bristol-Myers Squibb Company. Your use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy. |
|
|
